Table 2.
Subgroups analysis of combined HR for OS in HCC patients.
| Subgroups | NO. of studies | NO. of patients | Pooled HR | P-value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
| (95% CI) | I2 (%) | P-value | Model | ||||
| Sample size | |||||||
| <100 | 4 | 248 | 2.11 (1.29-3.46) | 0.003 | 57.2 | 0.071 | random |
| ≥100 | 5 | 2128 | 2.13 (1.61-2.81) | 0.000 | 51.4 | 0.084 | random |
| Region | |||||||
| Asian | 6 | 2146 | 1.93 (1.60-2.32) | 0.000 | 0 | 0.646 | random |
| Caucasian | 3 | 230 | 2.67 (1.11-6.44) | 0.029 | 85.9 | 0.001 | random |
| Cutoff value | |||||||
| ≤200 | 2 | 720 | 2.70 (0.97-7.50) | 0.057 | 62.8 | 0.101 | random |
| 200-400 | 4 | 721 | 2.00 (1.56-2.57) | 0.000 | 0 | 0.710 | random |
| ≥400 | 3 | 935 | 2.12 (1.14-3.94) | 0.018 | 84.2 | 0.002 | random |
| Tumor stage type | |||||||
| BCLC | 4 | 780 | 2.11 (1.40-3.17) | 0.000 | 77.8 | 0.004 | random |
| TNM | 2 | 1426 | 1.82 (1.39-2.38) | 0.000 | 0 | 0.754 | random |
| Others | 3 | 170 | 2.73 (1.53-4.89) | 0.001 | 20.6 | 0.284 | random |
| Therapy method | |||||||
| resection | 3 | 1189 | 1.95 (1.44-2.06) | 0.000 | 29.7 | 0.241 | random |
| TACE | 2 | 152 | 4.22 (2.53-7.04) | 0.000 | 0 | 0.817 | random |
| others | 4 | 1035 | 1.61 (1.35-1.93) | 0.000 | 0 | 0.392 | random |
Notes: HR: hazard ratio; 95% CI: 95% confidence intervals; OS: overall survival; NO: number; BCLC: Barcelona Clinic Liver Cancer; TNM: Tumor Node Metastasis; TACE: transcatheter arterial chemoembolization.